Loading
Zilovertamab vedotin is a ROR1-directed ADC in phase 3 for large B-cell lymphoma.
Zilovertamab vedotin is an anti-ROR1 antibody carrying the microtubule inhibitor MMAE through a cleavable linker; ROR1 is an oncofetal receptor re-expressed on B-cell cancers including large B-cell lymphoma and largely absent from normal adult tissue, which makes it an attractive ADC address. Merck acquired the programme through VelosBio and is developing it chiefly in large B-cell lymphoma. The waveLINE-003 phase 3 trial combines it at 1.75 mg/kg every 3 weeks with rituximab, gemcitabine and oxaliplatin (R-GemOx) in relapsed DLBCL, and it is also being tested in first line. Neutropenia, peripheral neuropathy and fatigue are the expected MMAE-class toxicities. Whether ROR1 targeting adds to existing CD19- and CD20-directed options, including CAR-T and bispecifics, is the question phase 3 must answer. It is an ADC against a fetal-type receptor that lymphoma cells switch back on.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Anti-ROR1 with MMAE. Connects to ROR1.
1.Antibody binds ROR1 on the tumour cell surface
Source: clinicaltrials.gov/study/NCT05139017. Doses are for orientation; the current label governs.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2020-11-05 | VelosBio to Merck & Co. (MSD) VLS-101, later zilovertamab vedotin (MK-2140), ROR1 ADC | Acquisition | not disclosed | $2.75bn | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
| Adverse event |
|---|
| Neutropenia |
| Peripheral neuropathy |
| Fatigue |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Zilovertamab vedotin" OR ABSTRACT:"Zilovertamab vedotin" OR TITLE:"MK-2140" OR ABSTRACT:"MK-2140") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zilovertamab vedotin, not a curated reading list.
Shares MMAE, Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
Shares ROR1, Diffuse large B-cell lymphoma.
Shares MMAE, Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
Shares MMAE, Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
Shares A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-, Merck & Co. (MSD).
Shares MMAE, Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).